Scroll to top

News Releases

Home
Investors
Newsroom

News Releases

Month Year

Month Year

Investor Alerts

Jul 30, 2019

Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8
Jul 16, 2019

Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer
Jun 24, 2019

Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
Jun 21, 2019

Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update

- Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated in Q3 2020 -
Jun 4, 2019

Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2ⁿᵈ Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway

- Results confirm IMU-935 as a potent inverse agonist of RORϒt with an IC₅₀ of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation -
May 30, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in June
May 9, 2019

Immunic, Inc. to Participate in Upcoming May Conferences
Apr 29, 2019

Immunic, Inc. Appoints Industry Veteran Tamara A. Seymour as Interim Chief Financial Officer
Apr 12, 2019

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

- Developing Oral Therapies with Best-in-Class Potential -
Apr 10, 2019

Vital Therapies, Inc. Announces Filing of its Form 10-Q for the Quarter Ended March 31, 2019

Show per page

We use cookies to give you the best experience.